ESMO-THE CHRISTIE
VIRTUAL PRECEPTORSHIP PROGRAMME
LUNG CANCER
Multidisciplinary management, standards of care and future perspectives
19-21 October 2020

CO-CHAIRS:
Fiona Blackhall, United Kingdom
Raffaele Califano, United Kingdom
Enriqueta Felip, Spain

SPEAKERS:
Mo Al Aloul, United Kingdom
Paul Baas, Netherlands
Haval Balata, United Kingdom
Neil Bayman, United Kingdom
Richard Booton, United Kingdom
Clara Chan, United Kingdom
Anne-Marie C. Dingemans, Netherlands
Simon Ekman, Sweden
Corinne Faivre-Finn, United Kingdom
Martin Früh, Switzerland
Pilar Garrido López, Spain
Keith M. Kerr, United Kingdom
Rohit Kochhar, United Kingdom
Cécile Le Pécouh, France
Catherine McBain, United Kingdom
Luis Paz-Ares, Spain
David Planchard, France
Suresh Senan, Netherlands
Yvonne Summers, United Kingdom
Paul Taylor, United Kingdom
Paul E. Van Schil, Belgium
Giulia Veronesi, Italy
David Woolf, United Kingdom

LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC

ACCREDITATION

The programme of this event has been accredited with 11 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

AstraZeneca  
MSD  
Takeda
**All timings are to be considered CEST (Central European Summer Time)**

### Monday, 19 October 2020

| 14:00-14:10 | Welcome and Introduction | Fiona Blackhall, UK  
| Raffaele Califano, UK  
| Enrique Felpin, ES |
| 14:10-15:20 | **SESSION 1**  
| Screening and diagnostics for lung cancer | Chair/Moderator:  
| Raffaele Califano, UK |
| 20’ | Lung cancer screening | Haval Balata, UK  
| 20’ | EBUS TBNA in diagnosis/staging of lung cancer | Richard Booton, UK  
| 20’ | Role of pathologist in diagnosis and mutation analysis of lung cancer | Keith M. Kerr, UK |
| 10’ | Discussion | Faculty |

| 15:20-15:30 | Break |

| 15:30-16:20 | **SESSION 1 - cont.**  
| Screening and diagnostics for lung cancer | Chairs/Moderators:  
| Fiona Blackhall, UK  
| Raffaele Califano, UK |
| 20’ | PET/CT in staging of lung cancer | Rohit Kochhar, UK  
| 20’ | Medical thoracoscopy in the management of thoracic malignancies | Mo Al Aloul, UK |
| 10’ | Discussion | Faculty |

| 16:20-17:50 | **SESSION 2**  
| Radical treatment of early stage NSCLC | Chair/Moderator:  
| Raffaele Califano, UK |
| 20’ | Surgery for early stage NSCLC | Giulia Veronesi, IT  
| 20’ | Stereotactic ablative RT for early stage NSCLC | Suresh Senan, NL  
| 20’ | Adjuvant RT for completely resected early stage NSCLC | Cécile Le Péchoux, FR  
| 20’ | Adjuvant chemotherapy for resected early stage NSCLC | Paul Taylor, UK |
| 10’ | Discussion | Faculty |

| 17:50-18:00 | **Close of day 1** |

### Tuesday, 20 October 2020

| 14:00-16:30 | **SESSION 3**  
| Advanced NSCLC | Chair/Moderator:  
| Fiona Blackhall, UK |
| 20’ | First-line chemotherapy for advanced NSCLC | David Planchard, FR  
| 20’ | First-line immune checkpoint blockade for NSCLC | Luis Paz-Ares, ES  
| 20’ | Treatment of EGFR mutant advanced NSCLC | Raffaele Califano, UK |
| 10’ | Discussion | Faculty |

| 15:10-15:20 | **Break** |
| 20’ | Treatment of ALK/ROS1 positive advanced NSCLC | Fiona Blackhall, UK  
<p>| 20’ | Maintenance treatment for advanced NSCLC | Yvonne Summers, UK |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chair/Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30-17:40</td>
<td>SESSION 4</td>
<td>Management of mesothelioma, oligometastatic NSCLC and brain metastases</td>
<td>Raffaele Califano, UK</td>
</tr>
<tr>
<td>20'</td>
<td>Discussion</td>
<td></td>
<td>Faculty</td>
</tr>
<tr>
<td>20'</td>
<td>Systemic treatment of mesothelioma</td>
<td>Paul Baas, NL</td>
<td></td>
</tr>
<tr>
<td>20'</td>
<td>Treatment of oligometastatic NSCLC</td>
<td>Anne-Marie C. Dingemans, NL</td>
<td></td>
</tr>
<tr>
<td>20'</td>
<td>Radical treatment of brain metastases: The importance of a neuro-oncology multidisciplinary approach</td>
<td>Catherine McBain, UK</td>
<td></td>
</tr>
<tr>
<td>17:40-17:45</td>
<td>Close of day 2</td>
<td></td>
<td>Fiona Blackhall, UK, Raffaele Califano, UK</td>
</tr>
</tbody>
</table>

**Wednesday, 21 October 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chair/Moderators</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-16:05</td>
<td>SESSION 5</td>
<td>Locally advanced NSCLC</td>
<td>Fiona Blackhall, UK, Enriqueta Felip, UK</td>
</tr>
<tr>
<td>20'</td>
<td>Treatment of locally advanced NSCLC in the elderly</td>
<td>David Woolf, UK</td>
<td></td>
</tr>
<tr>
<td>20'</td>
<td>Combined modality treatment for NSCLC with N2 disease</td>
<td>Clara Chan, UK</td>
<td></td>
</tr>
<tr>
<td>20'</td>
<td>Role of surgery for N2 disease</td>
<td>Paul E. Van Schil, BE</td>
<td></td>
</tr>
<tr>
<td>15:10-15:20</td>
<td>Coffee break</td>
<td></td>
<td>Faculty</td>
</tr>
<tr>
<td>45'</td>
<td>Participants clinical case discussion (3x15')</td>
<td>Faculty</td>
<td></td>
</tr>
</tbody>
</table>

Each 15 min slot for clinical case discussion includes 10' case presentation and 5' Q&A / interactive panel discussion

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chair/Moderators</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:05-17:55</td>
<td>SESSION 6</td>
<td>SCLC</td>
<td>Raffaele Califano, UK, Enriqueta Felip, ES</td>
</tr>
<tr>
<td>20'</td>
<td>Treatment of limited stage SCLC</td>
<td>Corinne Faivre-Finn, UK</td>
<td></td>
</tr>
<tr>
<td>20'</td>
<td>Chemotherapy for extensive stage SCLC</td>
<td>Martin Früh, CH</td>
<td></td>
</tr>
<tr>
<td>20'</td>
<td>Immune Checkpoint blockade for SCLC</td>
<td>Pilar Garrido López, ES</td>
<td></td>
</tr>
<tr>
<td>20'</td>
<td>Targeted agents in SCLC</td>
<td>Enriqueta Felip, ES</td>
<td></td>
</tr>
<tr>
<td>20'</td>
<td>Prophylactic cranial irradiation and role of thoracic RT for extensive stage SCLC</td>
<td>Neil Bayman, UK</td>
<td></td>
</tr>
<tr>
<td>17:55-18:00</td>
<td>Conclusion and farewell</td>
<td></td>
<td>Fiona Blackhall, UK, Raffaele Califano, UK, Enriqueta Felip, ES</td>
</tr>
</tbody>
</table>